Vienna, June 29th 2005 Preliminary results from a large-scale global study of people living with bipolar disorder,
1 presented today at the World Congress of Biological Psychiatry (WCBP), found that patient satisfaction with treatment is achieved through combining broad-based efficacy with a favourable tolerability profile.
The Thinking Ahead Survey,1 included 687 bipolar patients from seven countries (UK, US, Germany, Italy, Canada, Spain and Greece). These preliminary results indicate that:
- 88% of respondents said drug treatment satisfaction is largely influenced by how effective it is, followed then by patients experiencing few or manageable side effects (77%)
- 79% of respondents believe that a successful treatment would be one which leads to significant quality of life changes in terms of increased functionality and improved lifestyle
Bipolar disorder, also known as manic-depressive illness, is a severe biological disorder that affects approximately 3-4% of the adult population.5,6 More than half of those with bipolar disorder stop taking their medication at some point during their illness, subjecting themselves to a high risk of relapse and an increased risk of suicide.7
"As someone who lives with bipolar disorder I need a treatment which can control the manic symptoms but also treat the more disabling depressive symptoms," comments Michael Grinter, SEROQUEL patient and Thinking Ahead Taskforce member. "The treatment that I am currently taking, SEROQUEL, has brought an enormous benefit to my life in terms of controlling both poles of my mood and has enabled me to return to work and live a fully functioning life. It has provided me with the confidence to enjoy each day again."
Recently-published SEROQUEL (quetiapine) data in the Journal of Current Medical Research and Opinion confirm SEROQUEL's efficacy and tolerability in the treatment of bipolar mania symp
'"/>
Contact: Lisa O'Sullivan
lisa.o'sullivan@shirehealthinternational.com
44-207-108-6515
Shire Health International
29-Jun-2005
Page: 1 2 3 Related biology news :1.
New databases put wings on search for bipolar risk genes2.
$9M grant awarded to University of Cincinnati for bipolar disorder research3.
Genetic roots of bipolar disorder revealed by first genome-wide study of illness4.
Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults5.
Gene controlling circadian rhythms may be involved in onset of bipolar disorder6.
Extreme irritability -- is it childhood bipolar disorder?7.
Fear circuit flares as bipolar youth misread faces8.
Clock molecules sensitivity to lithium sheds light on bipolar disorder9.
Link suggested between regions on two chromosomes and bipolar disorder10.
Research zeros in on bipolar disorder genes, link with thyroid condition11.
Beyond lithium for bipolar disorder